PHASE 6 DELIVERABLE
Complete Preclinical Efficacy Development Program
AMX-B01 — Geniposide-Enriched Purified Botanical API
Document Code: SCF-AMMONEX-HE-AMXB01-P6-0001
Trigger Executed: EFFICACY PLAN
Development Stage: Pharmacology Validation & Proof-of-Concept Efficacy
Objective:
Generate robust nonclinical efficacy data demonstrating that AMX-B01 produces biologically meaningful improvements in ammonia homeostasis, hepatic nitrogen metabolism, gut–liver axis function, and neurological outcomes sufficient to justify progression into IND-enabling development.
1.0 EXECUTIVE EFFICACY STRATEGY
Primary Development Question
Can AMX-B01 produce reproducible reductions in ammonia burden while improving functional hepatic encephalopathy outcomes?
Primary Success Endpoints
Endpoint | Target |
Plasma ammonia | ≥30% reduction |
Urea-cycle biomarkers | Improvement |
Neuroinflammatory markers | Reduction |
Neurological performance | Improvement |
Survival (where applicable) | Improvement |
2.0 SCF EFFICACY ARCHITECTURE
HE Fault Node Coverage
Fault Node | AMX-B01 Objective |
Excess ammonia generation | Indirect reduction |
Hepatic nitrogen dysfunction | Direct modulation |
Gut barrier dysfunction | Secondary improvement |
Neuroinflammation | Direct modulation |
Astrocyte stress | Secondary improvement |
3.0 IN VITRO PHARMACOLOGY MATRIX
WORKSTREAM A
Hepatic Nitrogen Metabolism
Model Systems
- Primary human hepatocytes
- Human liver organoids
- Precision-cut liver slices
Endpoints
Endpoint | Measurement |
Urea production | Quantitative |
Ammonia clearance | Quantitative |
Citrulline production | Quantitative |
Ornithine production | Quantitative |
Cell viability | Quantitative |
Go Criteria
≥20% improvement versus control in nitrogen-handling endpoints.
WORKSTREAM B
Hyperammonemia Stress Model
Model
Ammonium chloride challenge
Endpoints
Endpoint | Measurement |
Cellular viability | Quantitative |
ATP levels | Quantitative |
ROS generation | Quantitative |
Mitochondrial function | Quantitative |
Success Criterion
Protection against ammonia-induced dysfunction.
WORKSTREAM C
Inflammatory Pharmacology
Cell Systems
- Human macrophages
- Kupffer cell models
- Microglial cell systems
Biomarkers
Marker | Goal |
TNF-α | Reduction |
IL-6 | Reduction |
CRP-associated signaling | Reduction |
NF-κB activation | Reduction |
WORKSTREAM D
Gut Barrier Program
Models
- Caco-2 monolayers
- Human intestinal organoids
Endpoints
Endpoint | Goal |
TEER | Increase |
Zonulin | Reduction |
Claudin-1 | Improvement |
Occludin | Improvement |
4.0 ORGANOID VALIDATION STRATEGY
Liver Organoid Program
Purpose
Validate nitrogen-metabolism activity.
Endpoints
- Urea synthesis
- Ammonia detoxification
- Mitochondrial resilience
- Transcriptomic response
Gut Organoid Program
Purpose
Assess gut-liver axis modulation.
Endpoints
- Barrier integrity
- Inflammatory signaling
- Tight-junction proteins
Brain Organoid Program
Purpose
Explore secondary neuroprotective effects.
Endpoints
- Cytokine signaling
- Oxidative stress markers
- Cellular viability
5.0 ANIMAL MODEL CASCADE
MODEL 1
Acute Hyperammonemia Rat
Purpose
Proof-of-concept efficacy.
Primary Endpoints
- Plasma ammonia
- Behavioral performance
- Survival
MODEL 2
Portal-Systemic Shunt Rat
Purpose
Hepatic encephalopathy simulation.
Endpoints
- Plasma ammonia
- EEG
- Neurological score
- Cytokines
MODEL 3
Bile Duct Ligation Model
Purpose
Cirrhosis-associated HE.
Endpoints
- Liver injury
- Fibrosis markers
- Plasma ammonia
- Neuroinflammation
MODEL 4
Carbon Tetrachloride Cirrhosis Model
Purpose
Chronic translational validation.
Endpoints
- Fibrosis
- Neurological outcomes
- Ammonia burden
- Survival
6.0 DOSE-RANGING PROGRAM
Objective
Define pharmacologically active exposure range.
Dose Levels
Exploratory
- Low dose
- Mid dose
- High dose
Specific dose selection must be informed by actual PK and toxicology findings and cannot be scientifically established yet.
Exposure Assessment
Measure:
- Plasma concentrations
- Liver concentrations
- Portal concentrations
Dose Selection Endpoint
Identify:
MED
Minimum Effective Dose
and
Optimal Biological Dose
7.0 BIOMARKER VALIDATION PLAN
Primary Biomarkers
Biomarker | Function |
Plasma ammonia | Primary efficacy |
Urea | Nitrogen metabolism |
Citrulline | Urea-cycle function |
Ornithine | Nitrogen metabolism |
Glutamine | Neurotoxicity marker |
Secondary Biomarkers
Biomarker | Function |
TNF-α | Neuroimmune activity |
IL-6 | Inflammatory activity |
CRP | Systemic inflammation |
LPS | Gut barrier dysfunction |
Exploratory Biomarkers
Biomarker | Function |
EEG | Neural activity |
Neurofilament light chain | Neural injury |
Cognitive testing | Clinical translation |
8.0 STATISTICAL ANALYSIS FRAMEWORK
Primary Analysis
Continuous Variables
Examples:
- Plasma ammonia
- Urea
- Cytokines
Analysis:
- Group comparison
- Dose-response evaluation
Secondary Analysis
Correlative Analysis
Evaluate:
Exposure
↓
Biomarker Response
↓
Functional Outcome
Translational Analysis
Determine relationship between:
- Liver exposure
- Ammonia reduction
- Neurological improvement
9.0 DEVELOPMENT CANDIDATE NOMINATION CRITERIA
Efficacy Criteria
Required
Endpoint | Threshold |
Plasma ammonia | ≥30% reduction |
Urea-cycle biomarkers | Improvement |
Neurological endpoints | Improvement |
Neuroinflammation | Reduction |
PK Criteria
Required
Endpoint | Threshold |
Oral exposure | Demonstrated |
Liver targeting | Demonstrated |
CNS exposure | Minimal |
Safety Criteria
Required
Endpoint | Threshold |
Clinical tolerability | Acceptable |
Organ toxicity | Absent or minimal |
Mortality | Acceptable |
10.0 GO / NO-GO MATRIX
GO
✓ Mechanistic activity demonstrated
✓ Biomarker response demonstrated
✓ Ammonia reduction achieved
✓ Favorable exposure profile
✓ Acceptable safety profile
NO-GO
✗ No ammonia reduction
✗ No biomarker response
✗ Poor PK profile
✗ Unacceptable toxicity
11.0 SCF TRANSLATIONAL READINESS SCORECARD
Domain | Status |
Pathophysiology Alignment | High |
Biomarker Strategy | High |
Translational Relevance | High |
PK/PD Integration | High |
Regulatory Readiness | Moderate |
12.0 PHASE 6 DECISION GATE
Advancement Criteria
✓ In vitro pharmacology completed
✓ Organoid validation completed
✓ Animal efficacy demonstrated
✓ Biomarker package validated
✓ Exposure-response relationship established
✓ Development candidate nomination justified
Status
ADVANCE TO PHASE 7
Required Next Trigger
TOX PLAN
Phase 7 will generate:
- Complete IND-enabling toxicology strategy
- Safety pharmacology package
- GLP toxicology program
- Genetic toxicology package
- Toxicokinetic strategy
- NOAEL determination framework
- Human risk assessment strategy
- IND safety package blueprint
MASTER REGISTRY INDEX
SCF-AMMONEX-HE-AMXB01-P6-0001 — Preclinical Efficacy Development Program
SCF-AMMONEX-HE-AMXB01-IVP-0002 — In Vitro Pharmacology Matrix
SCF-AMMONEX-HE-AMXB01-ORG-0003 — Organoid Validation Program
SCF-AMMONEX-HE-AMXB01-ANM-0004 — Animal Model Cascade
SCF-AMMONEX-HE-AMXB01-BIO-0005 — Biomarker Validation Program
SCF-AMMONEX-HE-AMXB01-STAT-0006 — Statistical Analysis Framework
SCF-AMMONEX-HE-AMXB01-P7-0007 — Toxicology Program Initiation